drugset / Trial / NCT02063230
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
Non-randomizedParallel-groupOpen-labelBasic science
Summary
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy subjects.
Timeline
- Start
- 2014-03
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selumetinib | Small molecule | 25 mg | Oral |
| Subject | Selumetinib | Small molecule | 50 mg | Oral |